Page last updated: 2024-11-06

floxuridine and Leukopenia

floxuridine has been researched along with Leukopenia in 20 studies

Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).

Research Excerpts

ExcerptRelevanceReference
"Twenty-four eligible patients (23 of whom were evaluated) with advanced and metastatic breast cancer were treated at the Saitama Cancer Center every 4 weeks with pirarubicin (30 mg/m2 i."9.09[Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer]. ( Higashi, Y; Inoue, K; Kurosumi, M; Suemasu, K; Tabei, T, 1999)
" The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer."9.07Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993)
"To evaluate the feasibility and efficacy of weekly paclitaxel and 5'-DFUR combination therapy in advanced or recurrent breast cancer, 13 patients were enrolled in this pilot study."7.72[Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer]. ( Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T, 2003)
"Two patients were diagnosed as advanced breast cancer with multiple bone metastases."5.33[Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)]. ( Kihara, M; Kontani, K; Yamauchi, A; Yokomise, H, 2005)
"Doxifluridine has therapeutic activity, albeit limited, in advanced rectosigmoid adenocarcinoma."5.27Phase II study of doxifluridine in advanced colorectal adenocarcinoma. ( Abele, R; Alberto, P; Cavalli, F; Hartmann, D; Hofmann, V; Holdener, EE; Kaplan, S; Ryssel, HJ; Siegenthaler, P, 1983)
"Twenty-four eligible patients (23 of whom were evaluated) with advanced and metastatic breast cancer were treated at the Saitama Cancer Center every 4 weeks with pirarubicin (30 mg/m2 i."5.09[Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer]. ( Higashi, Y; Inoue, K; Kurosumi, M; Suemasu, K; Tabei, T, 1999)
" The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer."5.07Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993)
"To evaluate the feasibility and efficacy of weekly paclitaxel and 5'-DFUR combination therapy in advanced or recurrent breast cancer, 13 patients were enrolled in this pilot study."3.72[Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer]. ( Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T, 2003)
"Leukocytopenia was more severe in group B."2.67[Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy] ( Ito, T; Komatsu, Y; Moriya, N; Ogasawara, H; Saito, S; Sakata, Y; Sugimoto, N; Tamura, Y; Tsushima, K; Yamada, Y, 1994)
"Two patients were diagnosed as advanced breast cancer with multiple bone metastases."1.33[Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)]. ( Kihara, M; Kontani, K; Yamauchi, A; Yokomise, H, 2005)
" However, a WHO grade 4 hematologic toxicity was observed in 9 patients, and 2 toxic deaths were related to severe granulocytopenia and sepsis."1.28[Doxifluridine toxicity, a fluorouracil analog with low myelosuppressive effect]. ( Alberto, P; Mermillod, B; Winkelmann, JJ, 1990)
"Doxifluridine has therapeutic activity, albeit limited, in advanced rectosigmoid adenocarcinoma."1.27Phase II study of doxifluridine in advanced colorectal adenocarcinoma. ( Abele, R; Alberto, P; Cavalli, F; Hartmann, D; Hofmann, V; Holdener, EE; Kaplan, S; Ryssel, HJ; Siegenthaler, P, 1983)
" The optimal daily dosage was considered to be 800-1,200 mg/body/day."1.27[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study]. ( Abe, O; Kimura, K; Kimura, T; Kurihara, M; Nakao, I; Niitani, H; Ohta, K; Saito, T; Urushizaki, I; Yoshida, Y, 1985)
"1% of cases; however, it was easily reduced by decreasing the dosage or discontinuing administration of the drug."1.27[Phase II study of 5'-DFUR in gastrointestinal and breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1985)
" 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines."1.27[Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT]. ( Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988)
"Stomatitis was severe at high doses of DFUR."1.26Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative. ( Abele, R; Alberto, P; Bollag, W; Germano, G; Heintz, R; Seematter, RJ, 1982)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-199011 (55.00)18.7374
1990's5 (25.00)18.2507
2000's4 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Huang, PY1
Mai, HQ1
Luo, DH1
Qiu, F1
Li, NW1
Xiang, YQ1
Chen, QY1
Zhang, L1
Sun, R1
Cao, KJ1
Guo, L1
Deng, MQ1
Mo, HY1
Guo, X1
Zhang, F1
Cao, SM1
Chen, MY1
Guo, Y1
Fan, YY1
Hu, W1
Hua, YJ1
Xie, GF1
Hong, MH1
Okamoto, Y1
Tominaga, T2
Okuyama, N1
Sawada, T1
Kou, Y1
HARTMANN, JR1
ORIGENES, ML1
MURPHY, ML1
SITARZ, A1
ERLANDSON, M1
ANSFIELD, FJ2
Kihara, M1
Kontani, K1
Yamauchi, A1
Yokomise, H1
Kemeny, N1
Eid, A1
Stockman, J1
Gonen, M1
Schwartz, L1
Tetzlaff, E1
Paty, P1
Abele, R2
Alberto, P3
Seematter, RJ1
Germano, G1
Heintz, R1
Bollag, W1
Kaplan, S1
Siegenthaler, P1
Hofmann, V1
Ryssel, HJ1
Hartmann, D1
Holdener, EE1
Cavalli, F1
Yamada, Y1
Tsushima, K1
Sakata, Y1
Saito, S1
Ito, T1
Sugimoto, N1
Ogasawara, H1
Tamura, Y1
Moriya, N1
Komatsu, Y1
Bajetta, E1
Colleoni, M1
Rosso, R1
Sobrero, A1
Amadori, D1
Comella, G1
Marangolo, M1
Scanni, A1
Lorusso, V1
Calabresi, F1
Inoue, K1
Tabei, T1
Suemasu, K1
Higashi, Y1
Kurosumi, M1
Lokich, J1
Moore, C1
Anderson, N1
Bern, M1
Winkelmann, JJ1
Mermillod, B1
Niitani, H1
Kimura, K1
Saito, T1
Nakao, I1
Abe, O1
Urushizaki, I1
Ohta, K1
Yoshida, Y1
Kimura, T1
Kurihara, M1
Kitamura, M1
Hayashi, K1
Takahashi, I1
Kosaki, G1
Ninomiya, Y1
Ryu, M1
Matsuura, N1
Fujimoto, K1
Miwa, M1
Ishitsuka, H1
Khazei, AM1
Patel, DD1
Morgenthaler, FR1
MacDonald, AJ1
Sanadizadeh, SM1
Watkins, E1
Moertel, CG1
Reitemeier, RJ1
Hahn, RG1
Ramirez, G1
DeConti, RC1
Kaplan, SR1
Papac, RJ1
Calabresi, P1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348]Early Phase 15 participants (Actual)Interventional2011-11-01Terminated (stopped due to Slow, insufficient accrual.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Serious and Non-Serious Adverse Events

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.

InterventionParticipants (Count of Participants)
1/Intravenous (IV) Tetrahydrouridine (THU)2

Frequency and Severity of Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0

[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions

Interventionadverse events (Number)
Day 1 Adverse EventsDay 2, Grade 2 HypoalbuminemiaDay 2, Grade 3 AnemiaDay 3 Adverse EventsDay 4 Adverse EventsDay 5 Adverse Events
1/Intravenous (IV) Tetrahydrouridine (THU)011000

Radiation Dosimetry Estimates of 5-fluoro-2'-Deoxycytidine (FdCyd) in Humans

Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year

InterventionmSv/MBq (Mean)
AdrenalsBrainBreastsGallbladder wallLower large intestine wallSmall intestineStomach wallUpper large intestine wallHeart wallKidneysLiverLungsMuscleOvariesPancreasRed marrowOsteogenic cellsSkinSpleenTestesThymusThyroidUrinary bladder wallUterus
1/Intravenous (IV) Tetrahydrouridine (THU)1.838.171.034.052.522.131.902.041.105.266.021.821.161.571.631.141.718.651.691.031.128.237.961.63

Tumor to Background Ratios (TBRs) of Target Lesions at 4 Time Points After Injection

Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection

InterventionTBR ratio (Number)
Pt 1 L. Parotid adenosquam. cell ca at 9 minPt 1 L. Parotid adenosquam. cell ca at 32 minPt 1 L. Parotid adenosquam. cell ca at 56 minPt 1 L. Parotid adenosquam. cell ca at 2 hrsPt 2 R. Parapharyngeal Spindle Cell Ca at 9 minPt 2 R. Parapharyngeal Spindle Cell Ca at 32 minPt 2 R. Parapharyngeal Spindle Cell Ca at 56 minPt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrsPt 3 Non-small Cell Lung Ca at 9 minPt 3 Non-small Cell Lung Ca at 32 minPt 3 Non-small Cell Lung Ca at 56 minPt 3 Non-small Cell Lung Ca at 2 hrsPt 4 Non-small Cell Lung Ca at 9 minPt 4 Non-small Cell Lung Ca at 32 minPt 4 Non-small Cell Lung Ca at 56 minPt 4 Non-small Cell Lung Ca at 2 hrsPt 5 Hepatocellular Ca at 9 minPt 5 Hepatocellular Ca at 32 minPt 5 Hepatocellular Ca at 56 minPt 5 Hepatocellular Ca at 2 hrs
1/Intravenous (IV) Tetrahydrouridine (THU)1.41.51.51.61.91.71.71.61.41.41.51.72.42.11.62.0NANANANA

Trials

6 trials available for floxuridine and Leukopenia

ArticleYear
Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:10

    Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therap

2009
Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma.
    Journal of surgical oncology, 2005, Aug-01, Volume: 91, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dexamethasone; Dose-

2005
[Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy]
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:7

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Ch

1994
Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans;

1993
[Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox

1999
A controlled comparison of 5-fluoro-2'-deoxyuridine therapy administered by rapid intravenous injection and by continuous intravenous infusion.
    Cancer research, 1967, Volume: 27, Issue:3

    Topics: Clinical Trials as Topic; Diarrhea; Drug Eruptions; Floxuridine; Humans; Hyperglycemia; Infusions, P

1967

Other Studies

14 other studies available for floxuridine and Leukopenia

ArticleYear
[Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr

2003
EFFECTS OF 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) AND 5-FLUOROURACIL (NSC-19893) ON CHILDHOOD LEUKEMIA.
    Cancer chemotherapy reports, 1964, Volume: 34

    Topics: Bone Marrow Examination; Child; Floxuridine; Fluorouracil; Leukemia; Leukopenia; Melena; Nausea; Tox

1964
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
    JAMA, 1964, Nov-16, Volume: 190

    Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid

1964
[Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:5

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast

2005
Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.
    Cancer treatment reports, 1982, Volume: 66, Issue:6

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation;

1982
Phase II study of doxifluridine in advanced colorectal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colonic Neoplasms

1983
Infusion of floxuridine plus etoposide plus cisplatin in human malignancies.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ci

1991
[Doxifluridine toxicity, a fluorouracil analog with low myelosuppressive effect].
    Bulletin du cancer, 1990, Volume: 77, Issue:3

    Topics: Administration, Oral; Antineoplastic Agents; Bone Marrow; Central Nervous System; Floxuridine; Heart

1990
[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:10

    Topics: Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Administration

1985
[Phase II study of 5'-DFUR in gastrointestinal and breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarr

1985
[Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:5

    Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marro

1988
Chronic infusion of 5-fluoro-2'-deoxyuridine (5-FUDR) into the hepatic artery of the dog.
    The Journal of surgical research, 1970, Volume: 10, Issue:8

    Topics: Animals; Diarrhea; Dogs; Female; Floxuridine; Gastrointestinal Hemorrhage; Hepatic Artery; Injection

1970
Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520).
    Cancer chemotherapy reports, 1971, Volume: 55, Issue:2

    Topics: Blood Cell Count; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Deoxyuridine; Female; Floxuridin

1971
Continuous intravenous infusions of 5-fluoro-2'-deoxyuridine in the treatment of solid tumors.
    Cancer, 1973, Volume: 31, Issue:4

    Topics: Breast Neoplasms; Diarrhea; Drug Eruptions; Female; Floxuridine; Gastrointestinal Neoplasms; Hemangi

1973